Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 12, 2014BMC CancerOpen Access

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGiles RobinsonSt. Jude Children's Research HospitalBOBrent A. OrrSt. Jude Children's Research Hospital
Amar Gajjar
Amar GajjarChildren's Oncology Group

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Robinson et al. (2014) studied this question.

synapsesocial.com/papers/6a812965176d2ce0316606fehttps://doi.org/10.1186/1471-2407-14-258
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vemurafenib in pediatric patients with <scp><i>BRAFV</i></scp><i>600E</i> mutated high‐grade gliomas2013 · 148 citations
  2. 2Oncogenic <i>BRAF</i> Mutation with <i>CDKN2A</i> Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas2010 · 249 citations
  3. 3Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma2012 · 2,163 citations
  4. 4<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors2012 · 1,040 citations